HRP20210697T1 - Antitijela i polipeptidi usmjereni protiv cd127 - Google Patents
Antitijela i polipeptidi usmjereni protiv cd127 Download PDFInfo
- Publication number
- HRP20210697T1 HRP20210697T1 HRP20210697TT HRP20210697T HRP20210697T1 HR P20210697 T1 HRP20210697 T1 HR P20210697T1 HR P20210697T T HRP20210697T T HR P20210697TT HR P20210697 T HRP20210697 T HR P20210697T HR P20210697 T1 HRP20210697 T1 HR P20210697T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- antigen
- binding
- fragment
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000049284 human IL7R Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Antitijelo ili njegov fragment za vezanje antigena, koje se specifično veže za CD127, posebno ljudski CD127, koje sadrži:
- laki lanac antitijela koji sadrži ili varijabilnu domenu lakog lanca antitijela koja se sastoji od sekvence odabrane iz grupe koja se sastoji od SEQ ID Br: 9; SEQ ID Br: 10; SEQ ID Br: 11; SEQ ID Br: 12; posebno SEQ ID Br: 12; i
- varijabilnu domenu teškog lanca antitijela koja se sastoji od sekvence prikazane u SEQ ID Br: 7.
2. Antitijelo ili njegov fragment za vezanje antigena prema patentnom zahtjevu 1, naznačeno time da je navedeno antitijelo humanizirano monoklonsko antitijelo, posebno pri čemu je konstantna domena lakog lanca antitijela izvedena iz konstantne domene ljudskog kapa lakog lanca, posebno pri čemu se konstantna domena lakog lanca sastoji od sekvence SEQ ID Br:27 ili 28, i pri čemu je konstantna domena teškog lanca antitijela izvedena iz ljudske konstantne domene teškog lanca IgG1, IgG2, IgG3, ili IgG4, posebno iz ljudske konstantne domene teškog lanca IgG4, posebno pri čemu se konstantna domena teškog lanca antitijela sastoji od sekvence sa SEQ ID Br:26.
3. Antitijelo ili njegov fragment za vezanje antigena prema patentnom zahtjevu 1 ili 2, naznačeno time da laki lanac antitijela sadrži ili se varijabilna domena lakog lanca antitijela sastoji od SEQ ID Br: 12.
4. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 3, koje je antagonist IL-7R signalizacije koju izaziva IL-7 i koje ne izaziva aktivaciju fosfatidil-inozitol 3 kinaze i/ili ERK signalnog puta.
5. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 4, koje prepoznaje epitop koji sadrži sekvencu uzetu sa 2b mjesta CD127 i/ili ometa vezanje CD127 sa yc zajedničkim lancem receptora citokina, posebno koje prepoznaje najmanje treći beta list 2b mjesta CD127.
6. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 5, koje ne izaziva internalizaciju CD127 i/ili inhibira internalizaciju CD127 koju izaziva IL-7.
7. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 6, koje ne povećava sazrijevanje dendritskih stanica koje je izazvano sa TSLP.
8. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 7, koje ima dugotrajni efekt i/ili brz efekt, posebno koje ima brz lokalni efekt.
9. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 8, koje se specifično veže sa ljudskim CD127 sa konstantnim afinitetom KD nižim od 5E-9 M, što se može utvrditi pomoću analize biosenzorom.
10. Kombinacija izoliranih molekula nukleinske kiseline koje kodiraju antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 9, posebno prva izolirana molekula nukleinske kiseline koja sadrži ili se sastoji od sekvence odabrane iz grupe koja se sastoji od SEQ ID Br: 15, SEQ ID Br: 16, SEQ ID Br: 17 i SEQ ID Br: 18; i druga izolirana molekula nukleinske kiseline koja sadrži ili se sastoji od sekvence SEQ ID Br: 13.
11. Farmaceutski pripravak koji sadrži antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 9 i/ili kombinaciju izoliranih molekula nukleinske kiseline prema patentnom zahtjevu 10, i farmaceutski vehikul.
12. Farmaceutski pripravak prema patentnom zahtjevu 11, koji je pogodan za lokalnu primjenu, posebno za lokalnu potkožnu, enteričku ili oralnu primjenu, preciznije za isporuku na debelo crijevo.
13. Komplet koji sadrži farmaceutski pripravak prema patentnom zahtjevu 11 ili patentnom zahtjevu 12 i uređaj za isporuku pogodan za lokalnu primjenu, naročito potkožni, enterički ili oralni uređaj za isporuku, preciznije navedeni uređaj koji sadrži prethodno napunjenu injekciju ili uređaj bez igle.
14. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 9, ili kombinacija izoliranih molekula nukleinske kiseline prema patentnom zahtjevu 10, ili farmaceutski pripravak prema patentnom zahtjevu 11 ili 12, za uporabu kao lijek.
15. Antitijelo ili njegov fragment za vezanje antigena prema bilo kojem od patentnih zahtjeva 1 do 9, ili kombinacija izoliranih molekula nukleinske kiseline prema patentnom zahtjevu 10, ili farmaceutski pripravak prema patentnom zahtjevu 11 ili 12, za uporabu prema patentnom zahtjevu 14 u sprečavanju ili liječenju odbacivanja transplantata organa ili tkiva ili bolesti odabrane iz grupe koja se sastoji od autoimunih bolesti, posebno reumatoidnog artritisa, sistemske skleroze, multiple skleroze, dijabetesa tipa I, autoimunog tiroiditisa, sistemskog eritemskog lupusa, primarnog Sjögren-ovog sindroma i upalnih bolesti, posebno upalne bolesti crijeva (IBD), preciznije Crohn-ove bolesti i ulceroznog kolitisa i encefalomijelitisa i alergijskih bolesti i bolesti raka i bolesti povezanih sa transplantacijom i respiratornim bolestima.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306655 | 2016-12-09 | ||
EP17835592.1A EP3551664B1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
PCT/EP2017/081911 WO2018104483A1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210697T1 true HRP20210697T1 (hr) | 2021-07-23 |
Family
ID=57796143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210697TT HRP20210697T1 (hr) | 2016-12-09 | 2021-05-05 | Antitijela i polipeptidi usmjereni protiv cd127 |
Country Status (37)
Country | Link |
---|---|
US (2) | US11098128B2 (hr) |
EP (1) | EP3551664B1 (hr) |
JP (1) | JP6986559B2 (hr) |
KR (1) | KR102306366B1 (hr) |
CN (1) | CN110392695B (hr) |
AR (1) | AR110326A1 (hr) |
AU (1) | AU2017373819B2 (hr) |
BR (1) | BR112019010595A2 (hr) |
CA (1) | CA3042582C (hr) |
CL (1) | CL2019001530A1 (hr) |
CO (1) | CO2019005909A2 (hr) |
CR (1) | CR20190273A (hr) |
CY (1) | CY1124153T1 (hr) |
DK (1) | DK3551664T3 (hr) |
EA (1) | EA201991005A1 (hr) |
ES (1) | ES2867900T3 (hr) |
HR (1) | HRP20210697T1 (hr) |
HU (1) | HUE054206T2 (hr) |
IL (1) | IL266837B (hr) |
LT (1) | LT3551664T (hr) |
MA (1) | MA49727B1 (hr) |
MD (1) | MD3551664T2 (hr) |
MX (1) | MX2019006577A (hr) |
MY (1) | MY190770A (hr) |
NZ (1) | NZ753213A (hr) |
PE (1) | PE20191152A1 (hr) |
PH (1) | PH12019501285A1 (hr) |
PL (1) | PL3551664T3 (hr) |
PT (1) | PT3551664T (hr) |
RS (1) | RS61808B1 (hr) |
RU (1) | RU2769352C2 (hr) |
SA (1) | SA519401906B1 (hr) |
SI (1) | SI3551664T1 (hr) |
TW (1) | TWI777996B (hr) |
UA (1) | UA126386C2 (hr) |
UY (1) | UY37511A (hr) |
WO (1) | WO2018104483A1 (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3066054A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
US11008395B2 (en) * | 2019-01-22 | 2021-05-18 | Bristol Myers-Squibb Company | Antibodies against IL-7R alpha subunit and uses thereof |
US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
CN114466864A (zh) * | 2019-06-21 | 2022-05-10 | 索瑞索制药公司 | 多肽 |
MX2022005411A (es) | 2019-11-05 | 2022-08-10 | Medikine Inc | COMPUESTOS DE UNIÓN A IL-2RßYC. |
CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
US11746139B2 (en) * | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
WO2023232826A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
BR112012018914A2 (pt) * | 2010-01-28 | 2017-07-25 | Glaxo Group Ltd | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." |
TWI596114B (zh) * | 2010-02-24 | 2017-08-21 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 CA CA3042582A patent/CA3042582C/en active Active
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active IP Right Grant
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/en active Active
- 2017-12-07 BR BR112019010595A patent/BR112019010595A2/pt unknown
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/en active Search and Examination
- 2017-12-07 UY UY0001037511A patent/UY37511A/es unknown
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
-
2019
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
- 2019-06-07 PH PH12019501285A patent/PH12019501285A1/en unknown
-
2021
- 2021-05-05 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210697T1 (hr) | Antitijela i polipeptidi usmjereni protiv cd127 | |
JP2020500542A5 (hr) | ||
Koneczny et al. | MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters | |
Pruenster et al. | Extracellular MRP8/14 is a regulator of β2 integrin-dependent neutrophil slow rolling and adhesion | |
RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
JP2015508757A5 (hr) | ||
UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
TWI691511B (zh) | 抗人類Notch4抗體 | |
BRPI0614040B8 (pt) | anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo | |
JP2017522903A5 (hr) | ||
JP2017505622A5 (hr) | ||
EA201390813A1 (ru) | Антитела и их применение | |
JP2019520034A5 (hr) | ||
RU2016151265A (ru) | Антитела, направленные на cd127 | |
BR112019016356A2 (pt) | anticorpo anti-sirpg humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação de antígeno, produto de combinação, método in vitro ou ex vivo, uso de pelo menos um anticorpo anti-sirpg de humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação ao antígeno, e, método in vitro de prever a resposta de um sujeito a um tratamento | |
JP2012527875A5 (hr) | ||
CN110087681A (zh) | 结合白细胞介素-2的抗体和其用途 | |
CN110305214A (zh) | 新型抗cd47抗体 | |
Berg et al. | Autoantibodies to muscarinic acetylcholine receptors found in patients with primary biliary cirrhosis | |
Kim et al. | A recently established murine model of nasal polyps demonstrates activation of B cells, as occurs in human nasal polyps | |
JP2018529635A5 (hr) | ||
BR112013020274A2 (pt) | substitutos de proteínas pós-traducionalmente modificadas e usos dos mesmos | |
CN108350064A (zh) | 针对细胞内抗原的单结构域抗体 | |
EP4219556A3 (en) | Human monoclonal antibodies specific for flt3 and uses thereof |